Children's Cancer Center, Staten Island University Hospital, Staten Island, New York.
Pediatr Blood Cancer. 2014 Jul;61(7):1329-35. doi: 10.1002/pbc.25017. Epub 2014 Mar 9.
Histiocytic disorders are rare entities that are becoming more recognized as our understanding of the molecular pathogenesis lead to novel diagnostic tests and targeted drug development. A symposium held at the American Society of Pediatric Hematology/Oncology (ASPHO) 2013 Annual Meeting discussed new insights into histiocytic disorders. This review highlights the symposium presentations, divided into three sections encompassing Langerhans cell histiocytosis (LCH), hemophagocytic lymphohistiocytosis (HLH) and Rosai Dorfman disease (RDD) including subsections on pathogenesis, clinical diagnostic criteria and novel insights into treatment. Details of other histiocytic disorders as well as the standard treatment guidelines have been published elsewhere and are beyond the scope of this discussion [Haupt et al. (2013). Pediatr Blood Cancer 60:175-184; Henter et al. (2007). Pediatr Blood Cancer 48:124-131].
组织细胞疾病较为罕见，但随着我们对其分子发病机制的理解不断深入，新的诊断检测方法和靶向药物研发也不断涌现。美国儿科血液学/肿瘤学会（ASPHO）2013 年年会的一次专题研讨会讨论了组织细胞疾病的新见解。本文重点介绍了研讨会的演讲内容，分为三个部分，涵盖朗格汉斯细胞组织细胞增生症（LCH）、噬血细胞性淋巴组织细胞增生症（HLH）和罗斯氏病（RDD），包括发病机制、临床诊断标准和治疗方面的新见解。其他组织细胞疾病的详细信息以及标准治疗指南已在其他地方发表，不在本次讨论范围之内[Haupt 等人（2013 年）。儿科血液学杂志 60：175-184；Henter 等人（2007 年）。儿科血液学杂志 48：124-131]。
